Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ATAI Life Sciences
(NASDAQ:ATAI)
Intraday
$1.77
-0.02
[-1.12%]
After-Hours
$1.77
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.77
-0.02
[-1.12%]
At close: Mar 28
$1.77
0
[0.00%]
PreMarket: 8:40AM EDT
Get Report
Watch
Q4 2023 earnings were released today before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for ATAI Life Sciences Stock (NASDAQ:ATAI)
ATAI Life Sciences Stock (NASDAQ: ATAI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 28, 2024
Recap: ATAI Life Sciences Q4 Earnings
Benzinga Insights
-
1 hour ago
ATAI Life Sciences Q4 EPS $(0.12) Beats $(0.16) Estimate, Sales $18.00K Miss $190.00K Estimate
Benzinga Newsdesk
-
1 hour ago
Wednesday, March 27, 2024
HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Maintains $20 Price Target
Benzinga Newsdesk
-
19 hours ago
Wednesday, March 20, 2024
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Lara Goldstein
-
Mar 20, 2024, 2:49PM
Saturday, March 16, 2024
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Lara Goldstein
-
Mar 16, 2024, 9:58AM
Thursday, March 14, 2024
Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
Benzinga Newsdesk
-
Mar 14, 2024, 12:42PM
Thursday, March 07, 2024
ATAI Life Sciences shares are trading higher in possible sympathy with MindMed, which received FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder.
Benzinga Newsdesk
-
Mar 7, 2024, 12:42PM
Monday, March 04, 2024
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Lara Goldstein
-
Mar 4, 2024, 1:48PM
atai Life Sciences Announces First Participant Dosed In Phase 1b Trial Of VLS-01
Benzinga Newsdesk
-
Mar 4, 2024, 8:08AM
Thursday, February 15, 2024
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein
-
Feb 15, 2024, 10:55AM
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Lara Goldstein
-
Feb 15, 2024, 8:36AM
Tuesday, February 06, 2024
atai Life Sciences Appoints Anne Johnson As CFO
Benzinga Newsdesk
-
Feb 6, 2024, 5:03PM
Saturday, January 27, 2024
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Lara Goldstein
-
Jan 27, 2024, 10:00AM
Monday, January 15, 2024
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein
-
Jan 15, 2024, 1:38PM
Friday, January 12, 2024
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Lara Goldstein
-
Jan 12, 2024, 4:55PM
Monday, January 08, 2024
Psyched: Psychedelics For Brain Injury, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, $50M For Atai And More
Lara Goldstein
-
Jan 8, 2024, 2:33PM
Saturday, January 06, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Maureen Meehan
-
Jan 6, 2024, 3:59PM
Thursday, January 04, 2024
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
Lara Goldstein
-
Jan 4, 2024, 2:31PM
Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
Lara Goldstein
-
Jan 4, 2024, 2:17PM
ATAI Life Sciences shares are trading higher after the company announced a strategic investment in Beckley Psytech Limited to accelerate the clinical development of short-duration psychedelics.
Benzinga Newsdesk
-
Jan 4, 2024, 11:39AM
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $20 Price Target
Benzinga Newsdesk
-
Jan 4, 2024, 10:46AM
ATAI Life Sciences Discloses Strategic Investment In Beckley Psytech To Accelerate Clinical Development Of Short-Duration Psychedelics
Benzinga Newsdesk
-
Jan 4, 2024, 7:23AM
Tuesday, January 02, 2024
atai Life Sciences shares are trading higher after the company announced topline results from its Phase 1 study evaluating orally administered EMP-01.
Benzinga Newsdesk
-
Jan 2, 2024, 11:55AM
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $20 Price Target
Benzinga Newsdesk
-
Jan 2, 2024, 10:41AM
atai Life Sciences Announces Results From Single Ascending Dose Phase 1 Study With EMP-01; Says EMP-01 Was Generally Well-Tolerated And Treatment-related Adverse Events Were As Expected
Benzinga Newsdesk
-
Jan 2, 2024, 8:04AM
Monday, January 01, 2024
Psychedelic Stock Gainers And Losers From January 1, 2024
Benzinga Insights
-
Jan 1, 2024, 4:30PM
Wednesday, December 27, 2023
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
Lara Goldstein
-
Dec 27, 2023, 10:09AM
Monday, December 18, 2023
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Lara Goldstein
-
Dec 18, 2023, 12:21PM
Monday, December 11, 2023
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
Lara Goldstein
-
Dec 11, 2023, 10:43AM
Tuesday, December 05, 2023
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Lara Goldstein
-
Dec 5, 2023, 10:12AM
Friday, November 24, 2023
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Lara Goldstein
-
Nov 24, 2023, 9:44AM
Thursday, November 23, 2023
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Benzinga Insights
-
Nov 23, 2023, 4:30PM
Tuesday, November 21, 2023
Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2
Lisa Levin
-
Nov 21, 2023, 6:30AM
Tuesday, November 14, 2023
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
Lara Goldstein
-
Nov 14, 2023, 2:13PM
Sunday, November 12, 2023
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Lara Goldstein
-
Nov 12, 2023, 8:39PM
Monday, November 06, 2023
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
Lara Goldstein
-
Nov 6, 2023, 7:02PM
Sunday, October 29, 2023
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoir And More
Lara Goldstein
-
Oct 29, 2023, 10:48PM
Sunday, October 22, 2023
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Lara Goldstein
-
Oct 22, 2023, 3:18PM
Monday, October 16, 2023
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Lara Goldstein
-
Oct 16, 2023, 3:57PM
Tuesday, October 10, 2023
Atai Life Sciences Announces Filing Of Early Warning Report
Benzinga Newsdesk
-
Oct 10, 2023, 8:08AM
Friday, October 06, 2023
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
Lara Goldstein
-
Oct 6, 2023, 5:07PM
Tuesday, October 03, 2023
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Lara Goldstein
-
Oct 3, 2023, 3:23PM
Monday, October 02, 2023
atai Life Sciences Reports Completion Of Phase 1 Study Of VLS-01 In Healthy Participants;
Benzinga Newsdesk
-
Oct 2, 2023, 4:15PM
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Lara Goldstein
-
Oct 2, 2023, 9:46AM
Tuesday, September 26, 2023
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Lara Goldstein
-
Sep 26, 2023, 9:28AM
Saturday, September 23, 2023
Exclusive Insights: How Tech Leaders Are Finding Balance Through Microdosing Psychedelics
Lara Goldstein
-
Sep 23, 2023, 3:22PM
Monday, September 18, 2023
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Lara Goldstein
-
Sep 18, 2023, 6:06PM
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Lara Goldstein
-
Sep 18, 2023, 3:10PM
Tuesday, September 12, 2023
Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years, NY Consulting Firm Predicts
Lara Goldstein
-
Sep 12, 2023, 4:35PM
Monday, September 11, 2023
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Lara Goldstein
-
Sep 11, 2023, 9:34AM
Show more